Literature DB >> 12223061

Fibroblast growth factors in cancer: therapeutic possibilities.

Michael Jeffers1, William J LaRochelle, Henri S Lichenstein.   

Abstract

The fibroblast growth factor (FGF) family of signalling molecules and its receptors (FGFRs) contribute to normal developmental and physiological processes. However, the subversion of this powerful growth stimulatory pathway has been implicated in the generation of a variety of pathological conditions. This review focuses on the role of FGF/FGFRs in cancer. The case will be made that this signalling pathway is associated with and functionally important for the growth of some human tumours. As such, FGF/FGFRs can be viewed as rational therapeutic oncology targets and strategies used to inhibit these molecules are discussed. The therapeutic exploitation of tumour-associated FGFR expression to deliver toxins or antiproliferative signals to tumour cells is also reviewed, as is the use of FGFs as protein therapeutics to alleviate the side effects of cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223061     DOI: 10.1517/14728222.6.4.469

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

1.  Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Authors:  Thomas Metzner; Alexandra Bedeir; Gerlinde Held; Barbara Peter-Vörösmarty; Sara Ghassemi; Christine Heinzle; Sabine Spiegl-Kreinecker; Brigitte Marian; Klaus Holzmann; Bettina Grasl-Kraupp; Christine Pirker; Michael Micksche; Walter Berger; Petra Heffeter; Michael Grusch
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

2.  Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.

Authors:  Vipin Yadav; Xiaoyi Zhang; Jiangang Liu; Shawn Estrem; Shuyu Li; Xue-Qian Gong; Sean Buchanan; James R Henry; James J Starling; Sheng-Bin Peng
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

3.  Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells.

Authors:  Zhiyong Liu; Yolanda E Hartman; Jason M Warram; Joseph A Knowles; Larissa Sweeny; Tong Zhou; Eben L Rosenthal
Journal:  Mol Cancer Res       Date:  2011-06-10       Impact factor: 5.852

4.  Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.

Authors:  Israel S Fernández; Pedro Cuevas; Javier Angulo; Pilar López-Navajas; Angeles Canales-Mayordomo; Rocío González-Corrochano; Rosa M Lozano; Serafín Valverde; Jesús Jiménez-Barbero; Antonio Romero; Guillermo Giménez-Gallego
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

5.  Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor.

Authors:  Larissa Sweeny; Zhiyong Liu; William Lancaster; Justin Hart; Yolanda E Hartman; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2012-03-27       Impact factor: 3.325

6.  A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Authors:  Martin H Voss; Cinta Hierro; Rebecca S Heist; James M Cleary; Funda Meric-Bernstam; Josep Tabernero; Filip Janku; Leena Gandhi; A John Iafrate; Darrell R Borger; Nobuya Ishii; Youyou Hu; Yulia Kirpicheva; Valerie Nicolas-Metral; Anna Pokorska-Bocci; Anne Vaslin Chessex; Claudio Zanna; Keith T Flaherty; Jose Baselga
Journal:  Clin Cancer Res       Date:  2019-02-11       Impact factor: 13.801

7.  Dendrimer-based tumor cell targeting of fibroblast growth factor-1.

Authors:  Thommey P Thomas; Rameshwer Shukla; Alina Kotlyar; Jola Kukowska-Latallo; James R Baker
Journal:  Bioorg Med Chem Lett       Date:  2009-12-03       Impact factor: 2.823

8.  Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.

Authors:  Dorothy M French; Benjamin C Lin; Manping Wang; Camellia Adams; Theresa Shek; Kathy Hötzel; Brad Bolon; Ronald Ferrando; Craig Blackmore; Kurt Schroeder; Luis A Rodriguez; Maria Hristopoulos; Rayna Venook; Avi Ashkenazi; Luc R Desnoyers
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

9.  Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.

Authors:  Hendrik Fischer; Ninon Taylor; Sigrid Allerstorfer; Michael Grusch; Gudrun Sonvilla; Klaus Holzmann; Ulrike Setinek; Leonilla Elbling; Heidelinde Cantonati; Bettina Grasl-Kraupp; Christine Gauglhofer; Brigitte Marian; Michael Micksche; Walter Berger
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.

Authors:  Roberta Lelis Dutra; Marcos Brasilino de Carvalho; Marcelo Dos Santos; Ana Maria da Cunha Mercante; Diana Gazito; Rafael de Cicco; Gencapo Group; Eloiza Helena Tajara; Iúri Drumond Louro; Adriana Madeira Álvares da Silva
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.